HS Code:
Cross-linked polyvinylbenzyltrimethylammonium chloride, commonly known as Cholestyramine Resin USP, is a pharmaceutical-grade resin used primarily as a bile acid sequestrant to lower cholesterol levels in the blood. It is classified under HS Code 39140000 (Ion-exchangers based on polymers of headings 3901 to 3913, in primary forms). This product is critical in the treatment of hypercholesterolemia and other conditions requiring bile acid binding. It is produced in limited quantities globally due to its specialized application and stringent regulatory requirements.
Total Trade Volume
Approximately USD 120 million
Data from 2022
Source
Data compiled from UN Comtrade Database and industry reports
USD 50 million
41.7% of total trade of total trade
Increasing
USD 30 million
25.0% of total trade of total trade
Increasing
USD 15 million
12.5% of total trade of total trade
Stable
USD 10 million
8.3% of total trade of total trade
Increasing
USD 8 million
6.7% of total trade of total trade
Stable
Average Rate
5.2% ad valorem
Highest Rate
10% (applied by certain developing countries)
Lowest Rate
0% (under free trade agreements like USMCA and EU-Japan EPA)
Rising demand for cholesterol-lowering drugs
Increased production and trade of Cholestyramine Resin due to growing prevalence of cardiovascular diseases globally
2021-2023
Shift towards generic formulations
Higher trade volumes from cost-effective producers like India, impacting pricing and market share of branded products
2020-2022
Regulatory harmonization in pharmaceutical standards
Facilitates smoother trade by reducing compliance costs, especially in regions like the EU and North America
2019-2023
The U.S. Food and Drug Administration approved a new generic version of Cholestyramine Resin USP, increasing market competition and accessibility.
March 2023
Expected to lower prices in the U.S. market and boost imports from cost-effective producers like India.
The European Union introduced stricter quality control measures for imported pharmaceutical resins, including Cholestyramine, to ensure compliance with EU pharmacopoeia standards.
July 2022
May increase compliance costs for exporters but ensures higher product safety and reliability in the EU market.
Major Indian pharmaceutical companies announced plans to expand production capacity for Cholestyramine Resin to meet growing global demand.
January 2023
Likely to solidify India's position as a leading exporter, potentially affecting global pricing dynamics.